Background: Persons with cognitive impairment may experience difficulties with language and cognition that interfere with their ability to make and communicate decisions. We developed an online visual tool to facilitate conversations about their preferences concerning supportive care.

Methods: We conducted Zoom interviews with persons with mild cognitive impairment (MCI) and mild to moderate dementia, using storytelling and a virtual tool designed to facilitate discussion. Each interview sought to discuss decision-making in the context of three scenarios, one concerning a past decision about supportive care, and two hypothetical scenarios based on decreasing abilities and increasing care needs. Interviewers shared their screen with the visual tool, which used the visual diagramming platform draw.io (https://www.drawio.com/) to create an online "canvas." Interviewers could drag icons (representing people, places, safety, emotions, activities, and issues) or type text onto the canvas to communicate concepts. We developed the tool with a multidisciplinary team of designers and researchers, and with input from people with cognitive impairment. Key user-centered design goals for the tool included focusing on simplicity, minimizing cognitive load, and using concepts and images that resonated with participants. We also used pilot interviews to refine interviewers' techniques for eliciting preferences with the tool. We examined the utility of the tool for engaging participants in dialogic interactions with the interviewer, and the cognitive and communicative processes exhibited by participants.

Results: We conducted fifteen interviews with persons with MCI, and mild or moderate dementia [mean age 77.8 years ± 7.1 (SD), 9 male, 6 female]. With respect to dialogic interactions, interviewers actively used the visualization technique to facilitate the conversation; participants engaged with the interface to varying degrees. Common communicative issues included participants being unresponsive to the question or providing unclear responses. During the sessions participants also exhibited uncertainty, introspection, and self-awareness.

Conclusion: We present a visual technique to engage persons with cognitive impairment in dialogue about complex decisions. We hope to explore the potential use of this technique in research, clinical, and community settings.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.094220DOI Listing

Publication Analysis

Top Keywords

cognitive impairment
16
persons cognitive
8
visual tool
8
interviews persons
8
mci mild
8
mild moderate
8
moderate dementia
8
dialogic interactions
8
tool
7
cognitive
6

Similar Publications

Background: The presence of multiple comorbid pathologic features in late-onset dementia has been well documented across cohort studies that incorporate autopsy evaluation. It is likely that such mixed pathology potentially confounds the results of interventional trials that are designed to target a solitary pathophysiologic mechanism in Alzheimer's disease and related dementias (ADRD).

Method: The UK ADRC autopsy database was screened for participants who had previously engaged in therapeutic interventional trials for Alzheimer's disease, vascular cognitive impairment, dementia, and/or ADRD prevention trials from 2005 to the present.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Clario, Philadelphia, PA, USA.

Background: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.

Method: ClinicalTrials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AIMST University, Bedong, Kedah, Malaysia.

Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!